These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Nanoscaled hydrated antimony (V) oxide as a new approach to first-line antileishmanial drugs. Franco AM; Grafova I; Soares FV; Gentile G; Wyrepkowski CD; Bolson MA; Sargentini É; Carfagna C; Leskelä M; Grafov A Int J Nanomedicine; 2016; 11():6771-6780. PubMed ID: 28008252 [TBL] [Abstract][Full Text] [Related]
9. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. Rojas R; Valderrama L; Valderrama M; Varona MX; Ouellette M; Saravia NG J Infect Dis; 2006 May; 193(10):1375-83. PubMed ID: 16619185 [TBL] [Abstract][Full Text] [Related]
10. Complexes of different nitrogen donor heterocyclic ligands with SbCl3 and PhSbCl2 as potential antileishmanial agents against Sb(III)-sensitive and -resistant parasites. Lizarazo-Jaimes EH; Reis PG; Bezerra FM; Rodrigues BL; Monte-Neto RL; Melo MN; Frézard F; Demicheli C J Inorg Biochem; 2014 Mar; 132():30-6. PubMed ID: 24412095 [TBL] [Abstract][Full Text] [Related]
11. Neolignan Licarin A presents effect against Leishmania (Leishmania) major associated with immunomodulation in vitro. Néris PL; Caldas JP; Rodrigues YK; Amorim FM; Leite JA; Rodrigues-Mascarenhas S; Barbosa-Filho JM; Rodrigues LC; Oliveira MR Exp Parasitol; 2013 Oct; 135(2):307-13. PubMed ID: 23891943 [TBL] [Abstract][Full Text] [Related]
12. Modulating aryl substitution: Does it play a role in the anti-leishmanial activity of a series of tetra-aryl Sb(V) fluorinated carboxylates? Artem'eva EV; Duffin RN; Munuganti S; Efremov AN; Andrews PC; Sharutina OK; Sharutin VV J Inorg Biochem; 2022 Sep; 234():111864. PubMed ID: 35636013 [TBL] [Abstract][Full Text] [Related]
13. Anti-leishmanial activity and cytotoxicity of a series of tris-aryl Sb(V) mandelate cyclometallate complexes. Duffin RN; Blair VL; Kedzierski L; Andrews PC J Inorg Biochem; 2020 Feb; 203():110932. PubMed ID: 31790875 [TBL] [Abstract][Full Text] [Related]
14. Antileishmanial activity of ruthenium(II)tetraammine nitrosyl complexes. Pereira JC; Carregaro V; Costa DL; da Silva JS; Cunha FQ; Franco DW Eur J Med Chem; 2010 Sep; 45(9):4180-7. PubMed ID: 20598778 [TBL] [Abstract][Full Text] [Related]
15. Disposition of antimony in rhesus monkeys infected with Leishmania braziliensis and treated with meglumine antimoniate. Friedrich K; Vieira FA; Porrozzi R; Marchevsky RS; Miekeley N; Grimaldi G; Paumgartten FJ J Toxicol Environ Health A; 2012; 75(2):63-75. PubMed ID: 22129235 [TBL] [Abstract][Full Text] [Related]
16. Synthesis of antimony complexes of yeast mannan and mannan derivatives and their effect on Leishmania-infected macrophages. Cantos G; Barbieri CL; Iacomini M; Gorin PA; Travassos LR Biochem J; 1993 Jan; 289 ( Pt 1)(Pt 1):155-60. PubMed ID: 8424752 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and characterization of bismuth(III) and antimony(V) porphyrins: high antileishmanial activity against antimony-resistant parasite. Gomes ML; DeFreitas-Silva G; dos Reis PG; Melo MN; Frézard F; Demicheli C; Idemori YM J Biol Inorg Chem; 2015 Jul; 20(5):771-9. PubMed ID: 25929728 [TBL] [Abstract][Full Text] [Related]
18. Antimonial susceptibility and in vivo behaviour of Leishmania major isolates collected in Algeria before and after treatment. Naouel E; Ihcene KD; Sofiane B; Khatima AO; Razika B; Bruno O; Zoubir H; Denis S Acta Trop; 2018 Apr; 180():7-11. PubMed ID: 29278674 [TBL] [Abstract][Full Text] [Related]
19. Investigation on the pharmacological profile of antimony(III) complexes with hydroxyquinoline derivatives: anti-trypanosomal activity and cytotoxicity against human leukemia cell lines. Reis DC; Pinto MC; Souza-Fagundes EM; Rocha LF; Pereira VR; Melo CM; Beraldo H Biometals; 2011 Aug; 24(4):595-601. PubMed ID: 21221718 [TBL] [Abstract][Full Text] [Related]
20. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis. Azeredo-Coutinho RB; Mendonça SC; Callahan H; Portal AC; Max G J Parasitol; 2007 Jun; 93(3):688-93. PubMed ID: 17626365 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]